Mark Kozloff to ErbB Receptors
This is a "connection" page, showing publications Mark Kozloff has written about ErbB Receptors.
Connection Strength
0.288
-
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
Score: 0.081
-
Cutaneous eruption related to human epidermal growth factor receptor inhibitors in stage IV colon cancer. Clin J Oncol Nurs. 2009 Oct; 13(5):491-3.
Score: 0.068
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.065
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.023
-
Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308.
Score: 0.019
-
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
Score: 0.017
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.016